4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Other_reagents > Adipogen/Curcumin (high purity)/AG-CN2-0059-M250/250 mg
商品详细Adipogen/Curcumin (high purity)/AG-CN2-0059-M250/250 mg
Adipogen/Curcumin (high purity)/AG-CN2-0059-M250/250 mg
Adipogen/Curcumin (high purity)/AG-CN2-0059-M250/250 mg
商品编号: AG-CN2-0059-M250
品牌: Adipogen Inc
市场价: ¥5300.00
美元价: 3180.00
产地: 美国(厂家直采)
公司:
产品分类: 其他试剂
公司分类: Other_reagents
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
MoreInformation
ProductDetails
SynonymsBRN2306965;CCRIS3257;NSC32982;NSC687842;CI75300
ProductTypeChemical
Properties
FormulaC21H20O6
MW368.4
MerckIndex14:2673
CAS458-37-7
Source/HostChemicalsSynthetic.Originallyisolatedfromturmeric(Curcumalonga).
PurityChemicals≥98%(HPLC)
AppearanceYellow-orangecrystallinepowder.
SolubilitySolubleinmethanol,ethanol,ethylacetate,acetone,methylenechloride,dimethylformamideormethylethylketone.
OtherProductDataNote:Thishighlypurifiedproductisfreeofdemethoxy-andbis-demethoxycurcuminanddoesnotcontain30-40%bioactiveimpurities
InChiKeyVFLDPWHFBUODDF-FCXRPNKRSA-N
ShippingandHandling
ShippingAMBIENT
ShortTermStorage+4°C
LongTermStorage-20°C
HandlingAdviceKeepcoolanddry.
Protectfromlight.
Use/StABIlityStableforatleast2yearsafterreceiptwhenstoredat-20°C.
Documents
MSDSDownloadPDF
ProductSpecificationSheet
DatasheetDownloadPDF
  • Anti-cancercompound.Interfereswithmultiplecellsignalingpathways,includingcellcycle(cyclinD1andcyclinE),apoptosis(activationofcaspasesanddown-regulationofanti-apoptoticgeneproducts),proliferation(HER-2,EGFRandAP-1),survival(PI3K/AKTpathway),invasion(MMP-9andadhesionmolecules),angiogenesis(VEGF),metastasis(CXCR-4)andinflammation(NF-κB,TNF,IL-6,IL-1,COX-2and5-LOX).
  • Anti-angiogenic.Anti-metastatic.Anti-invasive.Chemopreventive.
  • Sonichedgehog(Shh)signalingpathwaymodulator.DownregulatesShhandGli1.
  • Antioxidant.
  • Anti-inflammatory.PotentinhibitorofNF-κB,cyclooxygenase-2(COX-2),lipooxygenase(LOX),andinducIBLenitricoxidesynthase(iNOS;NOSII).DownregulatestheexpressionofvariousproinflammatorycytokinesincludingTNF,IL-1,IL-2,IL-6,IL-8,IL-12andchemokines.
  • Potentimmunomodulator.
  • Modulatesseveralkeytranscriptionfactors.Down-regulatetranscriptionfactorsNF-κB,AP-1andEgr-1.Down-regulatestheexpressionofCOX-2,LOX,NOS,MMP-9,uPA,TNF,chemokines,cellsurfaceadhesionmoleculesandcyclinD1.Down-regulategrowthfactorreceptors(suchasEGFRandHER2)andinhibitstheactivityofc-JunN-terminalkinase,proteintyrosinekinasesandproteinserine/threoninekinases.
  • Neuroprotective.Anti-amyloidactivity.
  • Cardioprotective.p300/CBP-HATinhibitor.
  • Regulateslipidmetabolismanddownregulatesobesity.Activatesperoxisomeproliferator-activatedreceptor-γ(PPARγ)andNrf2cell-signalingpathways.
  • Antiviral,antibacterial,antifungal.
  • Epigeneticagent.Interactswithhistonedeacetylases(HDACs),histoneacetyltransferases(HATs),DNAmethyltransferaseIandmicroRNAs.
  • Proteasomemodulator/inhibitor. 
  • Inducerofautophagyinlungadenocarcinomacells.
ProductReferences
  1. Anticancerpotentialofcurcumin:preclinicalandclinicalstudies:B.B.Aggarwal,etal.;AnticancerRes.23,363(2003)(Review)
  2. Curcumin:thestorysofar:R.A.Sharma,etal.;Eur.J.Cancer41,1955(2005)(Review)
  3. Curcumin,anatoxicantioxidantandnaturalNFkappaB,cyclooxygenase-2,lipooxygenase,andinduciblenitricoxidesynthaseinhibitor:ashieldagainstacuteandchronicdiseases:S.Bengmark;JPENJ.Parenter.Enteral.Nutr.30,45(2006)(Review)
  4. MultipleBIOLOGicalactivitiesofcurcumin:ashortreview:R.K.Maheshwari,etal.;LifeSci.78,2081(2006)(Review)
  5. "Spicingup"oftheimmunesystembycurcumin:G.C.Jagetia&B.B.Aggarwal;J.Clin.Immunol.27,19(2007)(Review)
  6. Curcumin:theIndiansolidgold:B.B.Aggarwal,etal.;Adv.Exp.Med.Biol.595,1(2007)(Review)
  7. Antioxidantandanti-inflammatorypropertiesofcurcumin:V.P.Menon&A.R.Sudheer;Adv.Exp.Med.Biol.595,105(2007)(Review)
  8. Modulationoftranscriptionfactorsbycurcumin:S.Shishodia,etal.;Adv.Exp.Med.Biol.595,127(2007)(Review)
  9. Antitumor,anti-invasion,andantimetastaticeffectsofcurcumin:G.Kuttan,etal.;Adv.Exp.Med.Biol.595,173(2007)(Review)
  10. Curcuminasaninhibitorofangiogenesis:S.S.Bhandarkar&J.L.Arbiser;Adv.Exp.Med.Biol.595,185(2007)(Review)
  11. Neuroprotectiveeffectsofcurcumin:G.M.Cole,etal.;Adv.Exp.Med.Biol.595,197(2007)(Review)
  12. Immunomodulationbycurcumin:S.C.Gautam,etal.;Adv.Exp.Med.Biol.595,321(2007)(Review)
  13. Curcuminandcancer:an"old-age"diseasewithan"age-old"solution:P.Anand,etal.;CancerLett.267,133(2008)(Review)
  14. Potentialtherapeuticeffectsofcurcumin,theanti-inflammatoryagent,againstneurodegenerative,cardiovascular,pulmonary,metabolic,autoimmuneandneoplasticdiseases:B.B.Aggarwal&K.B.Harikumar;Int.J.Biochem.CellBiol.41,40(2009)(Review)
  15. Theprotectiveroleofcurcuminincardiovasculardiseases:W.Wongcharoen&A.Phrommintikul;Int.J.Cardiol.133,145(2009)(Review)
  16. REVIEW:CurcuminandAlzheimer"sdisease:T.Hamaguchi,etal.;CNSNeurosci.Ther.16,285(2010)(Review)
  17. Targetinginflammation-inducedobesityandmetabolicdiseasesbycurcuminandothernutraceuticals:B.B.Aggarwal;Annu.Rev.Nutr.30,173(2010)(Review)
  18. Developmentofcurcuminasanepigeneticagent:S.Fu&R.Kurzrock;Cancer116,4670(2010)(Review)
  19. TheroleofnutraceuticalsintheregulationofWntandHedgehogsignalingincancer:F.H.Sarkar,etal.;CancerMetastasisRev.29,383(2010)(Review)
  20. Curcuminandobesity:evidenceandmechanisms:L.Alappat&A.B.Awad;Nutr.Rev.68,729(2010)(Review)
  21. Curcumin:ananti-inflammatorymoleculefromacurryspiceonthepathtocancertreatment:P.Basnet&N.Skalko-Basnet;Molecules16,4567(2011)(Review)
  22. Curcumin:apotentialneuroprotectiveagentinParkinson"sdisease:R.B.Mythri&M.M.Bharath;Curr.Pharm.Des.18,91(2012)(Review)
  23. CurcumininducesautophagyviaactivatingtheAMPKsignalingpathwayinlungadenocarcinomacells:K.Xiao,etal.;J.Pharmacol.Sci.123,102(2013)
  24. Targetingproteasomalpathwaysbydietarycurcuminforcancerpreventionandtreatment:N.Hasima&B.B.Aggarwal;Curr.Med.Chem.21,1583(2014)
  25. CurcuminattenuatesglutamateneurotoxicityinthehippocampusbysuppressionofERstress-associatedTXNIP/NLRP3inflammasomeactivationinamannerdependentonAMPK:Y.Li,etal.;Toxicol.Appl.Pharmacol.286,53(2015)
品牌介绍
Adipogen公司由三个子公司组成,分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国,运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发,如癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外,也可提供抗体和蛋白产品,Adipogen拥有自己的化学实验室,致力于开发创新型小分子化合物。